By Fineline Cube 
China‑based Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) and U.S. biotech firm Abalone Bio signed a cooperation agreement on October 30, 2025, to jointly advance next‑generation obesity treatments worldwide. The collaboration will focus on harnessing metabolism‑related G protein‑coupled receptors (GPCRs) to safely increase energy expenditure while preserving or boosting muscle mass.
Project Objectives and Technical Synergy
The R&D effort aims to overcome current weight‑loss therapy limitations by targeting and activating GPCR pathways that regulate energy balance and muscle physiology. Abalone Bio will contribute its proprietary GPCR antibody discovery platform, while Sihuan Pharmaceutical will bring metabolic‑disease expertise, full‑chain industrialization capabilities, and an established Greater China sales network to expedite development and commercialization.
Strategic Investment History and Value
Earlier this year, Sihuan Pharmaceutical completed a strategic investment in Abalone Bio, underscoring its commitment to obesity therapeutics. The firm’s investment track record includes a stake in UK‑based DJS Antibodies, which was later acquired by AbbVie for $255 million in 2022—highlighting the commercial potential of GPCR‑targeted antibody technologies.
Implications for the Global Obesity Market
The partnership is poised to fill a critical unmet need in the obesity treatment landscape by combining cutting‑edge antibody engineering with robust clinical development infrastructure. If successful, the joint venture could offer a differentiated therapy that enhances metabolic health without the adverse muscle‑loss effects seen with many existing agents, potentially reshaping the competitive dynamics of this high‑growth market.
For Investors
Sihuan Pharmaceutical’s move signals a growing belief in biologics as viable obesity solutions, while Abalone Bio’s participation could unlock new revenue streams for both companies. Market watchers will monitor pre‑clinical milestones and the first‑in‑class antibody candidates emerging from this alliance over the next 3‑5 years.-Fineline Info & Tech